У нас вы можете посмотреть бесплатно Trump's CBD Endorsement: Cannabis Stock Surge and Market Impact или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Cannabis stocks jump after Trump endorses CBD for seniors Why it matters: A new Truth Social video and statements from President Trump praising cannabidiol (CBD) for senior healthcare have revived hopes for U.S. cannabis rescheduling and Medicare coverage, sending U.S.-listed cannabis names and related plays sharply higher. Reuters reports premarket gains of ~20% in several cannabis stocks and a surge in the U.S. cannabis ETF. WINNERS Cannabis producers (U.S.-listed) Reason: An endorsement tied to senior healthcare plus ongoing rescheduling chatter raises expectations for demand, tax relief from Section 280E, and easier access to U.S. capital markets. Names: $TLRY (Tilray Brands), $CGC (Canopy Growth). U.S. cannabis exposure via ETFs Reason: Immediate, broad-based way to play a sector move; flows spike when headlines hit and rescheduling odds rise. Names: $MSOS (AdvisorShares Pure U.S. Cannabis ETF), $YOLO (AdvisorShares Pure Cannabis ETF). Strategic stakeholders and hemp/CBD consumer plays Reason: Portfolio stakes and distribution muscle could amplify upside if CBD gains mainstream, senior-focused coverage. Names: $STZ (Constellation Brands, major stake in $CGC), $MO (Altria, strategic stake in $CRON). LOSERS OTC pain and sleep brands Reason: If seniors shift to CBD for pain, inflammation, and sleep, legacy OTC categories face substitution and pricing pressure. Names: $KVUE (Tylenol, Motrin), $PRGO (store-brand OTC analgesics and sleep aids). Generic opioid and legacy pain portfolios Reason: Narrative rotation away from traditional prescription pain management toward non-opioid alternatives could weigh on volumes and sentiment. Names: $TEVA (generic pain portfolio), $HLN (Voltaren and other pain-care brands via ADR). Pharmacy benefit managers (PBMs) Reason: Any decline in prescription utilization from CBD adoption could compress rebate spreads and script-related economics over time. Names: $CI (Evernorth/Express Scripts), $UNH (Optum Rx). #CannabisStocks #CBD #SeniorsHealth #MSOS #Tilray #CanopyGrowth #StockMarket #Trading #Options #BreakingNewsToTradingMoves